Rofecoxi

Article Contents ::

Details About Generic Salt ::  Rofecoxi

Main Medicine Class:: Analgesic   

(roe-feh-cox-ib)>
Vioxx
Tablets: 12.5 mg
Tablets: 25 mg
Tablets: 50 mg
Class: Analgesic
NSAID

 Indications Relief of signs and symptoms of osteoarthritis and rheumatoid arthritis; treatment of primary dysmenorrhea; management of acute pain in adults.

 Contraindications History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs.

 Route/Dosage

Osteoarthritis: ADULTS: PO 12.5 to 25 mg once daily. Rheumatoid Arthritis: ADULTS: PO 25 mg once daily (max, 25 mg/day). Primary Dysmenorrhea and Management of Acute Pain: ADULTS: PO 50 mg once daily.

 Interactions

ACE inhibitors: Antihypertensive effects may be decreased. Aspirin: Risk of GI complications (eg, ulceration) may be increased. Lithium, methotrexate: Rofecoxib may increase plasma levels of these drugs, which may increase activity and adverse effects. Loop diuretics, thiazide diuretics: Diuretic effects may be decreased. Rifampin: May decrease rofecoxib plasma levels, which may cause a decrease in activity. Warfarin: The risk of bleeding may be increased.

 Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Hypertension; angina pectoris; irregular heartbeat; bradycardia; premature ventricular contraction; tachycardia; palpitations. CNS: Asthenia; fatigue; dizziness; headache; syncope; hypesthesia; insomnia; migraine; muscular spasm; parethesia; sciatica; somnolence; vertigo; anxiety; depression; decreased mental acuity. DERMATOLOGIC: Alopecia; atopic dermatitis; basal cell carcinoma; blister; cellulitis; contact dermatitis; nail disorder; perspiration; rash; pruritus; erythema; urticaria; xerosis. EENT: Sinusitis; dry mouth; esophagitis; blurred vision; cerumen impaction; conjunctivitis; dry throat; epistaxis; laryngitis; nasal congestion; nasal secretion; ophthalmic injection; otic pain; otitis; otitis media; pharyngitis; tinnitus; tonsillitis. GI: Abdominal pain, tenderness, and distension; GI bleeding; diarrhea; dyspepsia; epigastric discomfort; heartburn; duodenal ulcers; nausea; aphthous stomatitis; constipation; gas symptoms; dysgeusia; flatulence; gastritis; gastroenteritis; bloody stools; hemorrhoids; vomiting. GU: UTI; breast mass; cystitis; dysuria; menopausal symptoms; menstrual disorder; nocturia; urinary retention; vaginitis. METABOLIC: Hypercholesterolemia. RESPIRATORY: Upper respiratory tract infection; bronchitis; asthma; cough; dyspnea; pneumonia; pulmonary congestion. OTHER: Flu-like condition; pain; back pain; chest pain; pelvic pain; flushing; peripheral edema; upper extremity edema; allergy; muscle pain, cramp, stiffness, and weakness; myalgia.

 Precautions

Pregnancy: Category C. Avoid in late pregnancy because rofecoxib may cause premature closure of ductus arteriosus. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Initiate therapy with lowest recommended dose. Asthma: Use with caution in patients with pre-existing asthma. GI effects: Serious GI toxicity (eg, bleeding, ulceration, performation) can occur at any time, with or without warning symptoms. Renal disease: Use with caution. Liver disease: Not recommended in patients with moderate or severe hepatic insufficiency.

PATIENT CARE CONSIDERATIONS


 Administration/Storage

  • Store tablet and suspension at 25°C (77°F); excursions permitted to (59° to 86°F).
  • Shake suspension before use.
  • Administer orally using the lowest effective dose as prescribed for each patient.

 Assessment/Interventions

  • Assess for signs and symptoms of hypersensitivity.
  • Obtain a complete history of prescription and nonprescription drug use and any history of hypersensitivity.
  • Assess for possible drug interactions and potential adverse reactions.
  • Monitor for signs and symptoms of decreased renal function: serum creatinine, BUN, unexpected weight gain, edema.

 Patient/Family Education

  • Instruct patient to take the medication as prescribed.
  • Advise patient to inform primary care provider if taking or planning to take any OTC medications.
  • Stress the importance of promptly reporting signs or symptoms of GI ulceration or bleeding, skin rash, unexplained weight gain, or edema to primary caregiver.
  • Inform patients of the warning signs and symptoms of hepatotoxicity (eg, nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, flu-like symptoms) and to stop therapy and contact primary care provider should any of these occur.
  • Instruct patient to seek immediate emergency help in event of an anaphylactoid reaction.
  • Caution patient on prolonged corticosteroid therapy not to stop treatment abruptly but to taper the dosage slowly as directed by health care provider or primary caregiver if the decision has been to discontinue the medication.
  • Instruct women to inform their primary care giver if they are or plan to become pregnant.
  • Warn nursing mothers that a decision to discontinue the drug or nursing should be made in collaboration with their primary health care provider.
  • Instruct patient to report any unusual reaction or concern to primary care provider.

 

Drugs Class ::

(roe-feh-cox-ib)>
Vioxx
Tablets: 12.5 mg
Tablets: 25 mg
Tablets: 50 mg
Class: Analgesic
NSAID

Indications for Drugs ::

 Indications Relief of signs and symptoms of osteoarthritis and rheumatoid arthritis; treatment of primary dysmenorrhea; management of acute pain in adults.

Drug Dose ::

 Route/Dosage

Osteoarthritis: ADULTS: PO 12.5 to 25 mg once daily. Rheumatoid Arthritis: ADULTS: PO 25 mg once daily (max, 25 mg/day). Primary Dysmenorrhea and Management of Acute Pain: ADULTS: PO 50 mg once daily.

Contraindication ::

 Contraindications History of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Avoid in late pregnancy because rofecoxib may cause premature closure of ductus arteriosus. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly: Initiate therapy with lowest recommended dose. Asthma: Use with caution in patients with pre-existing asthma. GI effects: Serious GI toxicity (eg, bleeding, ulceration, performation) can occur at any time, with or without warning symptoms. Renal disease: Use with caution. Liver disease: Not recommended in patients with moderate or severe hepatic insufficiency.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Hypertension; angina pectoris; irregular heartbeat; bradycardia; premature ventricular contraction; tachycardia; palpitations. CNS: Asthenia; fatigue; dizziness; headache; syncope; hypesthesia; insomnia; migraine; muscular spasm; parethesia; sciatica; somnolence; vertigo; anxiety; depression; decreased mental acuity. DERMATOLOGIC: Alopecia; atopic dermatitis; basal cell carcinoma; blister; cellulitis; contact dermatitis; nail disorder; perspiration; rash; pruritus; erythema; urticaria; xerosis. EENT: Sinusitis; dry mouth; esophagitis; blurred vision; cerumen impaction; conjunctivitis; dry throat; epistaxis; laryngitis; nasal congestion; nasal secretion; ophthalmic injection; otic pain; otitis; otitis media; pharyngitis; tinnitus; tonsillitis. GI: Abdominal pain, tenderness, and distension; GI bleeding; diarrhea; dyspepsia; epigastric discomfort; heartburn; duodenal ulcers; nausea; aphthous stomatitis; constipation; gas symptoms; dysgeusia; flatulence; gastritis; gastroenteritis; bloody stools; hemorrhoids; vomiting. GU: UTI; breast mass; cystitis; dysuria; menopausal symptoms; menstrual disorder; nocturia; urinary retention; vaginitis. METABOLIC: Hypercholesterolemia. RESPIRATORY: Upper respiratory tract infection; bronchitis; asthma; cough; dyspnea; pneumonia; pulmonary congestion. OTHER: Flu-like condition; pain; back pain; chest pain; pelvic pain; flushing; peripheral edema; upper extremity edema; allergy; muscle pain, cramp, stiffness, and weakness; myalgia.

Drug Mode of Action ::  

(roe-feh-cox-ib)>
Vioxx
Tablets: 12.5 mg
Tablets: 25 mg
Tablets: 50 mg
Class: Analgesic
NSAID

Drug Interactions ::

 Interactions

ACE inhibitors: Antihypertensive effects may be decreased. Aspirin: Risk of GI complications (eg, ulceration) may be increased. Lithium, methotrexate: Rofecoxib may increase plasma levels of these drugs, which may increase activity and adverse effects. Loop diuretics, thiazide diuretics: Diuretic effects may be decreased. Rifampin: May decrease rofecoxib plasma levels, which may cause a decrease in activity. Warfarin: The risk of bleeding may be increased.

Drug Assesment ::

 Assessment/Interventions

  • Assess for signs and symptoms of hypersensitivity.
  • Obtain a complete history of prescription and nonprescription drug use and any history of hypersensitivity.
  • Assess for possible drug interactions and potential adverse reactions.
  • Monitor for signs and symptoms of decreased renal function: serum creatinine, BUN, unexpected weight gain, edema.

Drug Storage/Management ::

 Administration/Storage

  • Store tablet and suspension at 25°C (77°F); excursions permitted to (59° to 86°F).
  • Shake suspension before use.
  • Administer orally using the lowest effective dose as prescribed for each patient.

Drug Notes ::

 Patient/Family Education

  • Instruct patient to take the medication as prescribed.
  • Advise patient to inform primary care provider if taking or planning to take any OTC medications.
  • Stress the importance of promptly reporting signs or symptoms of GI ulceration or bleeding, skin rash, unexplained weight gain, or edema to primary caregiver.
  • Inform patients of the warning signs and symptoms of hepatotoxicity (eg, nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, flu-like symptoms) and to stop therapy and contact primary care provider should any of these occur.
  • Instruct patient to seek immediate emergency help in event of an anaphylactoid reaction.
  • Caution patient on prolonged corticosteroid therapy not to stop treatment abruptly but to taper the dosage slowly as directed by health care provider or primary caregiver if the decision has been to discontinue the medication.
  • Instruct women to inform their primary care giver if they are or plan to become pregnant.
  • Warn nursing mothers that a decision to discontinue the drug or nursing should be made in collaboration with their primary health care provider.
  • Instruct patient to report any unusual reaction or concern to primary care provider.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

Leave a comment

Your email address will not be published. Required fields are marked *

royalmpo Royalmpo Royalmpo royalmpo royalmpo royalmpo royalmpo https://malangtoday.id/ https://guyonanbola.com/ renunganhariankatolik.web.id royalmpo royalmpo royalmpo dewaslot168 ri188 https://hayzlett.com/c-suite-network/ kingslot jkt88 mpodewa https://going-natural.com/the-story-behind-the-mutilated-scalp-video/ royalmpo/ pisang88/ langkahcurang/ mpohoki/ mpocuan/ royalmpo/ mporoyal/ asiaslot/ rajaslot138/ royalmpo https://hayzlett.com/news/ rajaslot88/ Analisis Scatter Hitam MahjongWays RTP Terukur Kemenangan Puluhan Grid Fase Awal Mahjong Pola Perilaku Pemain Harian Prediksi Strategi Game Terbaik RTP Strategi Target Kemenangan Tekanan Meja Live Kasino Slot Digital Hiburan Ringan Slot Online Tanpa Target Mengelola Mood Pemain Slot https://going-natural.com/my-braid-locs/ https://going-natural.com/kellen-marcus/ narutoslot bangslot royalmpo royalmpo macanasia bosslot slotking gacorway
Strategi Analitik Platform Game Dalam Mengelola Variasi Pola Permainan Online Di Era Windows 12 Pendekatan Data Driven Dalam Memahami Ritme Sistem Permainan Digital Pada Ekosistem Android Modern Studi Dinamika Platform Gaming Melalui Distribusi Kombinasi Simbol Di Tengah Popularitas Xbox Game Pass Analisis Strategi Modern Dalam Mengelola Volatilitas Sistem Permainan Digital Saat Tren Nintendo Kembali Naik Framework Pengolahan Data Gaming Untuk Menjaga Stabilitas Pola Permainan Dalam Era Gemini AI Tools Teori Permainan Mahjong Ways Dalam Analisa Intensitas Sistem RTP Online Pada Perangkat Smartphone Modern Pendekatan Sistematis Dalam Menganalisis Pola Permainan Pada Ekosistem Gaming Setelah Discord Down Model Evaluasi Strategi Platform Game Melalui Observasi Pergerakan Algoritma Setelah Update iOS 26.3.1 Strategi Adaptif Dalam Mengelola Ritme Permainan Pada Platform Digital Dengan Dukungan Windows 12 Pendekatan Data Analitik Untuk Mengidentifikasi Pola Sistem Permainan Mobile Pada Samsung Galaxy S26 Ultra
Studi Adaptasi Strategi Permainan Mahjong Dalam Sistem Platform Digital Di Tengah Tren Nintendo Gaming Analisis Teknologi Gaming Platform Dalam Evolusi Sistem Permainan Berbasis RTP Di Era Gemini AI Pendekatan Sistematik Dalam Analisis Algoritma Permainan Mobile Saat Dark Mode Twitter Kembali Trending Studi Pola Mahjong Ways Dalam Perspektif Strategi Platform Game Pada Perangkat Smartphone Modern Analisis Perkembangan Algoritma Platform Gaming Dalam Sistem Permainan Pada Era Xbox Game Pass Pendekatan Manajemen Risiko Permainan Mobile Dalam Ekosistem Gaming Android Generasi Baru Strategi Pengamatan Sistem Permainan Dalam Lingkungan Platform Game Modern Saat Windows 12 Dibahas Evaluasi Sistem Gaming Platform Dalam Mengelola Variasi Pola Permainan Pada Perangkat Samsung Galaxy Framework Analitik Permainan Digital Dalam Mengelola Variasi Sistem Game Saat Re9 Update Dibahas Gamer Studi Dinamika Platform Game Melalui Pendekatan Analisis Data Di Era Apple Newsroom Digital Model Framework Strategi Permainan Digital Dalam Platform Gaming Berbasis Android Modern Strategi Pengelolaan Sistem Permainan Melalui Pendekatan Data Analitik Pada Infrastruktur Cloud Gaming Analisis Adaptasi Sistem Permainan Dalam Ekosistem Gaming Digital Saat Project Helix Menjadi Sorotan Pendekatan Modern Dalam Analisis Pola Permainan Berbasis Data Saat Gemini AI Digunakan Developer Evaluasi Dinamika Sistem Permainan Digital Melalui Observasi Data Pada Sistem iOS 26.3.1 Studi Struktur Sistem Game Dalam Perspektif Teknologi Gaming Di Tengah Tren Nintendo Global Pendekatan Framework Gaming Dalam Mengelola Pola Permainan Digital Di Tengah Popularitas Mario Day Analisis Perubahan Pola Mahjong Wins Dalam Ekosistem Gaming Modern Saat Re9 Update Diperbincangkan Model Analitik Pola Permainan Mahjong Dalam Sistem Platform Digital Modern Berbasis Android Studi Evolusi Teknologi Gaming Dalam Pengembangan Platform Permainan Pada Sistem Windows 12 Strategi Modern Membaca Sistem Permainan Digital Berbasis Algoritma Pada Infrastruktur Cloud Gaming Evaluasi Sistem Platform Game Dalam Dinamika Permainan Online Pada Era Smartphone Modern Pendekatan Data Platform Dalam Mengidentifikasi Pola Permainan Online Pada Infrastruktur TV App Strategi Pengolahan Data Gaming Dalam Mengelola Pola Permainan RTP Pada Infrastruktur Gaming Cloud Strategi Pengelolaan Pola Permainan Melalui Analisis Platform Digital Saat iPhone Generasi Baru Dirilis Pendekatan Analitik Sistem Game Dalam Mengelola Ritme Permainan Pada Era Xbox Game Pass Strategi Data Driven Dalam Menganalisis Pola Sistem Permainan Digital Pada Infrastruktur Cloud Studi Algoritma Permainan Mahjong Dalam Perspektif Platform Gaming Pada Ekosistem Android Analisis Sistem Permainan Digital Dalam Kerangka Strategi Platform Game Di Era Apple Ecosystem Dinamika Sistem Permainan Mahjong Digital Melalui Observasi Ritme Algoritma Pada Ekosistem Gaming Mobile Modern Pola Mahjong Ways 2 Hari Ini Strategi Malam Mahjong Wins 3 Kisah Sukses Andi Grid Mahjong & Starlight Saksi Mata: Mode Manual Mahjong Wins RTP Bertahap Pragmatic Spiral Pola Mahjong Ways Kurikulum Jackpot Respon Mahjong Wins 3 Lebih Cepat Akselerasi Free Spin Mahjong Wins3